In an analysis column in the British Medical Journal, York University's Joel Lexchin and Donald Light from the University of Medicine and Dentistry of New Jersey say that the "widely touted 'innovation crisis' in pharmaceuticals is a myth," and that the real problem in pharma is that current incentives reward companies for making drugs that are only marginally better than existing products.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.